The spirometer rarely decides the inhaler. In most high-income health systems, the formulary does. Asthma care is shaped less by the flow-volume loop than by which controller sits on the preferred tier, and by the paperwork required to prescribe anything else. This piece explains how coverage rules redirect treatment steps, where equity gaps open, and what practice teams can do without waiting for plan design to change.

The Spirometer Sits Idle

Spirometry confirms variable airflow obstruction and guides step-up therapy. Guidelines place it near the start of the diagnostic pathway. Yet in many US and EU practices, a prior authorisation request for a controller inhaler arrives before the test is booked. The order of operations reverses: coverage first, confirmation later.

Clinicians learn the formulary before they learn the flow-volume loop. A practice nurse can recite which ICS-LABA combination is preferred by the three largest local plans. The same nurse may struggle to recall the last time a spirometry result changed the prescription. That is not clinical laziness. It is adaptation to the gate that actually opens.

The consequence is a diagnostic pathway that bends toward coverage. A patient with symptoms consistent with asthma may be started on a preferred controller while spirometry waits for a slot. If the preferred agent fails, the documented failure becomes the ticket to the next tier. The test becomes retrospective justification rather than prospective guidance.

There is a quieter cost too. Spirometry done late is spirometry done less well. A patient started on an inhaled corticosteroid before testing may show a blunted bronchodilator response, and the reversibility that would have confirmed the diagnosis never appears on the tracing. The clinician is then left interpreting a test that the treatment has already edited, and the note has to explain why the numbers look better than the history.

Formulary Tiers Rewrite Treatment Steps

Step-up therapy in asthma follows a logic of control and escalation. Formulary tiers follow a logic of rebates and preferred status. When the two logics diverge, the tier usually wins. A patient stable on a non-preferred ICS-LABA may be switched to a preferred alternative at renewal, not because control worsened but because the plan changed its list.

Non-preferred inhalers typically require documented failure of the preferred agent first. That means a trial period, often measured in weeks, during which symptoms may persist. The guideline-concordant choice sits behind a step that the guideline does not recognise. Clinicians document the failure to satisfy the plan, then prescribe what they wanted in the first place.

The trial period has a hidden arithmetic. A patient who needs four weeks to fail a preferred agent, then two weeks for the PA to clear, then another few weeks to reach therapeutic effect on the right drug, has spent roughly two months in partial control. That is two months of night waking, of reliever overuse, of missed work and school. None of it appears in the plan's cost calculation, because the plan does not pay for it directly.

This site has argued that inhaler costs stay flat while admissions vary. The formulary layer helps explain why: the same device price can mask different access pathways. A cheap preferred inhaler that patients cannot tolerate is not cheap care.

Prior Authorisation as Clinical Gatekeeper

Prior authorisation requests for asthma controllers demand a trial of the preferred agent, a documented diagnosis, and often spirometry values. Turnaround times range from a few hours to several weeks depending on the plan and the completeness of the submission. During that window, the patient needs something.

What they often get is oral steroids. A short course of prednisolone bridges the gap while the paperwork moves. Repeated courses carry cumulative risk: bone density, glucose control, mood. The formulary delay becomes a clinical exposure that no guideline recommends.

The burden falls on practice staff. A single PA may require a fax, a phone call, a portal upload, and a follow-up. Small practices without dedicated administrative staff absorb this into clinical time. The result is fewer PA submissions, more abandoned prescriptions, and patients who quietly stop asking.

Completeness matters more than eloquence. Reviewers work from a checklist, and a request that answers every line moves faster than one that argues the clinical case at length but omits the trial date. I have seen the same patient approved on a second submission that differed only in attaching the pharmacy fill history and the date the preferred agent was first dispensed.

Equity Gaps in Coverage Design

High-deductible plans deter controller uptake. A patient who must pay the first several hundred dollars out of pocket may fill the reliever and skip the preventer. The reliever is cheap and fast. The controller is expensive and invisible when it works. Cost-related non-adherence looks like poor self-management until someone asks about the deductible.

Rural patients face pharmacy network gaps. A preferred inhaler may be available at a chain pharmacy forty minutes away, not at the local one. Mail order helps some and fails others, particularly those without reliable delivery addresses or broadband. The formulary assumes a pharmacy that may not exist in the patient's county.

Medicaid formularies vary widely by state, and out-of-pocket caps remain uneven across plans. A related piece on guidelines stalling at the primary care gate describes a similar dynamic: the protocol exists, the gate does not open. Asthma coverage design produces the same gap between what is recommended and what is reachable.

Children carry a particular version of this. A controller prescribed for a child on a high-deductible family plan competes with every other cost in the household budget, and the parent making that trade-off is not being careless. They are prioritising. When the school nurse reports more reliever visits in the autumn, the formulary is somewhere in that story.

What Clinicians Can Do Within Constraints

Document peak flow variability before submitting a PA. A diary with morning and evening readings over two weeks gives the reviewer something to approve. Spirometry attached to the request shortens the review. The goal is to make the clinical case legible to a non-clinician reading a checklist.

Use payer-specific appeal templates. Most large plans publish their criteria, and many have a standard appeal form. A template that mirrors the plan's language, with spirometry and trial history attached, wins more often than a free-text letter. Keep the templates in a shared folder and update them when the formulary changes.

Flag cost-related non-adherence at every review. Ask which inhaler the patient actually fills, not which one was prescribed. A patient who skips the controller to afford the reliever will not volunteer that unless asked directly. The question takes ten seconds and changes the plan.

This site has also noted how screening can find disease that systems cannot treat. Asthma spirometry risks the same fate when the treatment it confirms sits behind a PA. The test is only useful if the prescription it justifies can be filled.

Practical Steps for Practice Teams

Map the top three local formularies quarterly. Assign one staff member to check preferred inhalers for the plans that cover most of the practice. Post the list where prescriptions are written. A formulary that changes in January should not surprise the practice in March.

Build a PA checklist for preferred inhalers. Include the diagnosis code, spirometry date, trial history, and the specific plan criterion being met. A checklist reduces denials from incomplete submissions and shortens the turnaround when the request is resubmitted.

Schedule spirometry before the first controller request. If the test slot is weeks out, document why the controller was started first and what will trigger a review. The note protects the clinical reasoning and gives the PA reviewer a timeline.

Track denial reasons and share them with plan representatives. A pattern of denials for the same missing document is a conversation the practice can have with the plan's provider relations team. Aggregate data gets more attention than individual appeals.

Review inhaler technique at each coverage change. A switch to a different device is a new technique, not a like-for-like substitution. The patient who used a dry powder inhaler correctly may misuse the new pressurised device. Ten minutes at the switch prevents a failed trial that was never a fair test.

Keep a short note of what the switch actually cost the patient in time and money. When a plan reviews its formulary, practices that can describe the downstream effect in concrete terms have more standing than those that argue principle alone.

This article is informational and does not constitute personalised medical advice. Readers should consult a qualified clinician for decisions about their own care.